| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Edesa Biotech, Inc.$7.01
-0.01 (-0.14%)
D 24Pipeline Score Richly Valued Pharma · Clinical
Market Cap
93.01 M
EPS
-1.34
P/E Ratio
-
Value Trade
1.02 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.77 M
Total Assets
12.38 M
Total Liabilities
12.38 M
Equity
10.20 M
D/E Ratio
12,345
-28.41 %
Week
41.93 %
1 Month
1,070.15 %
3 Month
518.93 %
6 Month
-77.32 %
5 Year
-99.06 %
All Time
Cash Data
Cash Position
10.00 M
Monthly Burn
1.43 M
Runway
5.3 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
50.61 K
52 Week Range
0.72 - 20.32
% held by Insiders
20.27 %
% held by Institutions
39.08 %
Enterprise Value
91.38 M
Total Shares
7.04 M
Short %
7.87 %
Float Shares
3.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Edesa Biotech, Inc.
270Total events
2Upcoming
51Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 2
Event history 268
Jun 5, 2026
◆Oral PresentationparidiprubartPresentation
Oral presentation of exploratory data from paridiprubart study in AKI at ERA Congress
Acute Kidney Injurysource ↗
Jun 5, 2026
▲Full ResultsparidiprubartClinical Data
Exploratory AKI data from Phase 2 and Phase 3 studies reported
acute kidney injurysource ↗
Jun 2026
◆Oral PresentationparidiprubartPresentation
Additional data presentation on paridiprubart in AKI at ERA Congress
Acute Kidney Injurysource ↗
Jun 2026
◆Trial InitiationEB06Trial
Preparations for Phase 2 study of EB06 in vitiligo; site activations and patient recruitment expected to begin midyear 2026
moderate-to-severe nonsegmental vitiligosource ↗
May 20, 2026
◆Oral PresentationparidiprubartPresentation
Full oral presentation of Phase 3 results at ATS 2026 International Conference
Acute Respiratory Distress Syndromesource ↗
May 19, 2026
May 15, 2026
●Oral PresentationPresentation
Edesa to participate in Respiratory Innovation Summit, ATS 2026, Dermatology Drug Development Summit, and BIO International Convention
May 15, 2026
◆Oral PresentationparidiprubartPresentation
Oral Showcase presentation at ATS 2026 Respiratory Innovation Summit
Acute Respiratory Distress Syndromesource ↗
May 15, 2026
◆Poster PresentationparidiprubartPresentation
Poster presentation at ATS 2026 Respiratory Innovation Summit
Acute Respiratory Distress Syndromesource ↗
May 14, 2026
May 14, 2026
▲Full ResultsparidiprubartClinical Data
Additional positive Phase 3 data for paridiprubart in ARDS; consistent treatment benefits across subgroups
Acute Respiratory Distress Syndromesource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $6M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankEdesa Biotech, Inc. faces pipeline headwinds (24/100), with $561M risk-adjusted pipeline value, led by 4L PegLyte + bisacodyl in Colonoscopy (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4L PegLyte + bisacodyl Small molecule | Colonoscopy | Phase 3 | NCT02976805 | 49% | $471M | COMPLETED | 196 | - | - | Feb 19, 2020 | - | Feb 21, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
paridiprubart | acute kidney injury | Phase 3 | 2026-06-05 | 28 day mortality: paridiprubart plus SOC 33% (95% CI: 28%–39%), placebo plus SOC 49% (95% CI: 41%–57%), relative reduction 32% (nominal p<0.005); MAKE30: paridiprubart plus SOC 41% (95% CI: 36%–46%), placebo plus SOC 53% (95% CI: 47%–60%), relative reduction 23% (nominal p<0.005) Read More | Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury Read More | |
paridiprubart | acute kidney injury | Phase 3 | 2026-06-05 | 28 day mortality: paridiprubart plus SOC 33% (95% CI: 28%–39%), placebo plus SOC 49% (95% CI: 41%–57%), relative reduction 32% (nominal p<0.005); MAKE30: paridiprubart plus SOC 41% (95% CI: 36%–46%), placebo plus SOC 53% (95% CI: 47%–60%), relative reduction 23% (nominal p<0.005) Read More | Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury Read More | |
paridiprubart | acute kidney injury | Phase 3 | 2026-06-05 | 28 day mortality: paridiprubart plus SOC 33% (95% CI: 28%–39%), placebo plus SOC 49% (95% CI: 41%–57%), relative reduction 32% (nominal p<0.005); MAKE30: paridiprubart plus SOC 41% (95% CI: 36%–46%), placebo plus SOC 53% (95% CI: 47%–60%), relative reduction 23% (nominal p<0.005) Read More | Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EDSA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EDSA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EDSA▲ +8.4%on this news· ran to +20% by day 3
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Edesa Biotech has announced a $3.5 million private placement of common shares, led by its CEO and healthcare-focused investors. The financing is expected to close around June 15, 2026, and will support the company's vitiligo program and general corporate purposes. The shares will be sold at $4.69 each for investors and $5.21 for the CEO.
Read more →EDSA▼ -23%on this news
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech has reported positive exploratory data for paridiprubart, an anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The findings indicate a significant reduction in mortality and improvements in kidney-specific outcomes. These results will be presented at the 63rd European Renal Association Congress, reinforcing the rationale for further development of paridiprubart in AKI.
Read more →EDSA▲ +32.8%on this news
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
Edesa Biotech will present new data on paridiprubart, an anti-TLR4 antibody, at the upcoming ERA Congress in Glasgow. This presentation will focus on exploratory data from a study involving patients with acute kidney injury and respiratory distress. The company aims to highlight the drug's potential in addressing a critical medical need, given the lack of targeted therapies for AKI.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2026 Results
Edesa Biotech reported its fiscal second-quarter results, highlighting progress in its clinical programs. The company is preparing for a Phase 2 study of EB06 in vitiligo and has shared encouraging data from its Phase 3 study of paridiprubart for Acute Respiratory Distress Syndrome. Despite a reported net loss, Edesa remains optimistic about its pipeline and upcoming clinical milestones.
Read more →EDSA▲ +6.1%on this news· ran to +17% by day 1
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Edesa Biotech has announced that its CEO, Dr. Par Nijhawan, will present findings from the Phase 3 study of paridiprubart at the ATS 2026 Respiratory Innovation Summit. The study demonstrated statistically significant mortality reductions in ARDS patients. The presentation is scheduled for May 15, 2026, showcasing the potential of this first-in-class anti-TLR4 antibody.
Read more →EDSA▼ -10.8%on this news
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
Edesa Biotech has announced progress on its Phase 2 clinical study of EB06 for nonsegmental vitiligo, with enrollment expected to begin in mid-2026. The company has selected JSS Medical Research as its CRO and has started outreach to clinical sites. EB06, a monoclonal antibody targeting CXCL10, aims to address the autoimmune nature of vitiligo, which currently has limited treatment options.
Read more →EDSA▲ +68%on this news· ran to +145% by day 3
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
Edesa Biotech has reported additional positive results from its Phase 3 study of paridiprubart, showing a significant reduction in 28-day mortality among a diverse patient population. The treatment demonstrated consistent benefits across various severity groups and comorbidities. Edesa plans to advance regulatory discussions and explore strategic partnerships based on these findings.
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2026 Results
Edesa Biotech, Inc. has released its fiscal results for the first quarter ended December 31, 2025. The company has made strides in manufacturing its EB06 drug candidate for vitiligo, with recruitment expected to begin mid-2026, pending regulatory approvals. They also reported positive results from a Phase 3 study of their drug paridiprubart in respiratory conditions. Despite these advancements, Edesa posted a net loss of $2.2 million and faced increased operational costs compared to the previous year.
Read more →EDSAEdesa Biotech Reports Fiscal Year 2025 Results
Edesa Biotech reported its financial results for the fiscal year ended September 30, 2025, showcasing progress in its clinical programs. The company successfully completed a Phase 3 study of its monoclonal antibody paridiprubart, while also initiating preparations for a Phase 2 study of EB06 in nonsegmental vitiligo. Despite reporting a net loss of $7.2 million, Edesa highlighted improvements in their financial position and plans to seek strategic partnerships to support ongoing and future development endeavors.
Read more →EDSA▼ -6.5%on this news
Edesa Biotech Announces Upcoming Conference Schedule
Edesa Biotech, Inc. has announced its participation in several upcoming conferences, highlighting its focus on developing host-directed therapeutics for immuno-inflammatory diseases. The company is advancing its clinical pipeline, which includes treatments for conditions such as vitiligo and Acute Respiratory Distress Syndrome. Edesa's management encourages scheduling meetings during these events for further discussions.
Read more →EDSA▼ -17.9%on this news· ran to -29% by day 3shared move
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech announced positive results from its Phase 3 study of paridiprubart for treating Acute Respiratory Distress Syndrome (ARDS). The study met primary and secondary endpoints, showing significant reductions in mortality and the need for invasive mechanical ventilation. The drug demonstrated a durable survival benefit and was well-tolerated among patients. Edesa's CEO expressed optimism about the drug's potential as a standard of care for ARDS.
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech reported its fiscal 3rd quarter 2025 results, highlighting progress in manufacturing for its drug candidate EB06, aimed at treating vitiligo. The company anticipates submitting drug manufacturing data to the FDA by the end of 2025. Despite a net loss reported for the quarter, management remains optimistic about the potential of EB06.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2025 Results
Edesa Biotech, Inc. announced its fiscal results for the second quarter of 2025, revealing a focus on developing its vitiligo drug candidate, EB06. The company secured $15 million in equity financing to advance the program and has begun regulatory preparations for a Phase 2 study in the U.S. Financial results showed a reduction in operating expenses and a smaller net loss compared to the previous year. Edesa plans to participate in the upcoming BIO International Convention to enhance investor engagement and promote its initiatives.
Read more →EDSAEdesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech, Inc. will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto. The company's management is scheduled to present on May 5 at 4:00 PM ET. Edesa is focused on developing therapeutics for immuno-inflammatory diseases, with a clinical pipeline that includes candidates for vitiligo and Acute Respiratory Distress Syndrome.
Read more →EDSA▼ -5.6%on this news
Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux. Weiler brings significant experience from various roles in the biotech sector, including leadership positions at Exzell Pharma and Cipher Pharmaceuticals. CEO Par Nijhawan expressed confidence in Weiler's ability to advance the company's pipeline and strategic opportunities.
Read more →EDSA▼ -17.2%on this news
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech, Inc. reported its fiscal 1st quarter results for 2025, showing advancements in its anti-CXCL10 monoclonal antibody candidate EB06 aimed at treating vitiligo. The company is preparing for a clinical trial, with regulatory data submission expected by mid-2025. Financially, Edesa reflected a net loss of $1.6 million, though it strengthened its capital position with a $15 million capital raise. Overall, the company is optimistic about its vitiligo program and future funding opportunities, despite facing potential risks with regulatory approvals and product efficacy.
Read more →EDSA▲ +74.7%on this newsshared move
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Edesa Biotech has successfully completed a private placement, raising approximately $15 million by selling Series B-1 convertible preferred shares and common shares. The funds will primarily support the advancement of EB06, a monoclonal antibody for nonsegmental vitiligo, into Phase 2 clinical trials. The offering was led by Velan Capital, with participation from various investors.
Read more →EDSA▲ +7.6%on this news
Edesa Biotech Reports Fiscal Year 2024 Results
Edesa Biotech, Inc. reported its fiscal year 2024 results, indicating a strategic pivot to a government-funded study on its anti-TLR4 drug candidate in patients with Acute Respiratory Distress Syndrome (ARDS). The company experienced a decrease in total operating expenses and validated its technology with a third government award. However, Edesa still reported a net loss of $6.2 million, highlighting challenges in its financial position despite prudent management strategies. The company is expected to submit an investigational new drug application for its anti-CXCL10 program and aims to maximize synergies between its government-funded projects.
Read more →EDSAEdesa Biotech’s Founder Makes Strategic Investment in the Company
Edesa Biotech has announced a strategic investment agreement with an entity affiliated with CEO and founder Dr. Par Nijhawan, who will invest up to $5.0 million, including an initial $1.5 million. The investment includes the purchase of Series A-1 Convertible Preferred Shares and related Warrants under Nasdaq rules. Dr. Nijhawan expressed strong confidence in the company’s growth and development pipeline. However, shareholder approval will be needed for parts of the investment exceeding $2.0 million, and there are inherent risks in achieving the projected future success.
Read more →EDSA▼ -5.5%on this news
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
Edesa Biotech, Inc. announced its fiscal third-quarter results for 2024, reporting decreased operating expenses and a net loss of $1.7 million. The company’s anti-TLR4 drug candidate, EB05, was selected for a U.S. government-funded study aimed at treating ARDS, which presents potential avenues for value creation. Edesa also plans to progress its vitiligo and pulmonary fibrosis programs with an Investigational New Drug application planned for submission. Overall, the company shows commitment to financial prudence while advancing its clinical pipeline.
Read more →EDSABARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) du
Edesa Biotech's drug, paridiprubart (EB05), has been selected by BARDA for a Phase 2 clinical trial focused on acute respiratory distress syndrome (ARDS). This trial will investigate the drug's efficacy in hospitalized patients with ARDS stemming from diverse causes. With promising previous results showing a significant reduction in mortality among critically ill patients, the ongoing study aims to further support the potential of paridiprubart as a standard-of-care treatment. Additionally, Edesa is pursuing parallel Phase 3 studies that build on these findings.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2024 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech, a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of fiscal 2024, indicating decreased operating expenses and improved financial performance compared to the previous year. The company is progressing with its Phase 3 study of EB05 for Acute Respiratory Distress Syndrome and plans additional trials for pulmonary fibrosis and vitiligo. Edesa has also secured funding from the Canadian government to bolster its development activities. Management anticipates significant milestones over the next 12 to 24 months.
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2024 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech, Inc. reported its financial results for the first quarter of fiscal 2024, highlighting a net loss of $1.7 million. The company secured up to C$23 million in funding from the Canadian government for its ARDS drug candidate, EB05, and is advancing its clinical trials for both EB05 and a monoclonal antibody in vitiligo patients. Edesa's management noted positive momentum with regulatory agencies and partnerships, aiming to leverage its financial resources to expand development activities. Despite a slight increase in expenses, the company is on track for key regulatory submissions and continues to explore partnerships.
Read more →EDSAEdesa Biotech Reports Fiscal Year 2023 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech, Inc. reported its financial results for the fiscal year ending September 30, 2023, highlighting significant achievements and funding developments. The company reported favorable outcomes from clinical studies and secured up to C$23 million from the Canadian government for its ARDS drug candidate, EB05. Despite an annual net loss of $8.4 million, the company noted a reduction in operational expenses and is well-positioned for 2024 with plans for further clinical activities. Edesa aims to advance its drug development pipeline while seeking additional funding opportunities.
Read more →EDSA▲ +80.7%on this news
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government TORONTO, ON / ACCESSWIRE /
Edesa Biotech has announced a commitment of up to C$23 million in funding from the Canadian government for its pivotal Phase 3 clinical study of the therapeutic candidate EB05, aimed at treating acute respiratory distress syndrome (ARDS). The funding, part of the Strategic Innovation Fund, is designed to enhance research efforts and potentially expand access to the promising therapy. EB05 has demonstrated a significant reduction in mortality during earlier trials, showcasing its potential impact on critical care. Edesa plans to use the funding for operational costs and preparing for commercialization if the trials succeed.
Read more →EDSA▼ -32.7%on this newsshared move
Edesa Biotech Announces One-for-Seven Reverse Share Split TORONTO, ON / ACCESSWIRE /
Edesa Biotech, Inc. has announced a one-for-seven reverse share split effective October 11, 2023. This action will consolidate every seven shares into one, aiming to enhance the perception of its stock value while allowing trading to continue under the same symbol on The Nasdaq Capital Market. Shareholders will automatically see adjustments in their holdings without needing to take any action. However, this move may carry implications regarding the company's performance and position in the market.
Read more →EDSAEdesa Biotech Reports Fiscal Third Quarter 2023 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech, Inc. has reported its financial results for the fiscal third quarter of 2023, highlighting positive outcomes from a university study of its monoclonal antibody, paridiprubart, which shows promise against respiratory pathogens. Alongside this, Edesa achieved regulatory milestones for its drug candidates and effectively managed operational costs, leading to notable reductions in expenses. Despite these advancements, the company still faces financial challenges, reporting significant net losses for the quarter and year-to-date.
Read more →EDSAEdesa Biotech Appoints Biotech Deal Veteran to CFO Role TORONTO, ON / ACCESSWIRE /
Edesa Biotech, a clinical-stage biopharmaceutical company, has appointed Stephen Lemieux as its new Chief Financial Officer, effective July 15, 2023. Lemieux, a CPA with two decades of experience in the healthcare sector, is expected to bring valuable insights and leadership to the company's financial strategies. His familiarity with Edesa's operations is seen as an asset for achieving corporate milestones. Edesa's CEO expresses confidence in Lemieux’s ability to drive growth and value creation for shareholders.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2023 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech, Inc. reported its fiscal 2nd quarter 2023 results with positive developments, including two regulatory milestones: FDA's agreement on the Phase 3 study of EB05 for ARDS and Canadian authorization for a Phase 2 study of EB06 for vitiligo. The company also shared promising topline results from its ongoing Phase 2b study of EB01 for chronic allergic contact dermatitis. Despite these advancements, Edesa reported a net loss of $2.33 million during the quarter, although operating expenses have significantly decreased compared to the same period last year. Management remains optimistic about growth opportunities and plans to broaden the use of its lead biologic, paridiprubart.
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2023 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech recently reported its fiscal first quarter 2023 results, highlighting important advancements in its clinical programs. The company received Fast Track designation from the FDA for its drug candidate EB05 aimed at treating Acute Respiratory Distress Syndrome. Additionally, preliminary results from a Phase 2b study of EB01 showed significant efficacy in treating Allergic Contact Dermatitis. Edesa also announced Canadian regulatory approval for a Phase 2 clinical study of EB06 for vitiligo, reflecting growth and momentum despite ongoing financial challenges.
Read more →EDSAEdesa Biotech Reports Fiscal Year 2022 Results TORONTO, ON / ACCESSWIRE /
edsa_ex991.htm EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2022 Results TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial
Read more →EDSAEdesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market TORONTO, ON / ACCESSWIRE /
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market TORONTO, ON / ACCESSWIRE / November 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-rela
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2022 Results Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIR
edsa_ex991.htm EXHIBIT 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Ede
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2022 Results TORONTO, ON / ACCESSWIRE /
edsa_ex991.htm EXHIBIT 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financia
Read more →EDSA▼ -13.1%on this news
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules TORONTO, ON / ACCESSWIRE /
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2022 Results TORONTO, ON / ACCESSWIRE /
edsa_ex991.htm EXHIBIT 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2022 Results TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported fin
Read more →EDSAEdesa Biotech Reports Fiscal Year 2021 Results TORONTO, ON / ACCESSWIRE /
edsa_ex991.htm EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2021 Results TORONTO, ON / ACCESSWIRE / December 28, 2021/ Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial r
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and ni
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2021 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six mon
Read more →EDSAEdesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares TORONTO, ON / ACCESSWIRE /
Announces $3.5 Million Bought Deal Offering of Common Shares / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into an underwr
Read more →EDSAEdesa Biotech Reports Fiscal First Quarter 2021 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal First Quarter 2021 ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ende
Read more →EDSAEdesa Biotech Receives C$14 million for COVID-19 Study TORONTO, ON / ACCESSWIRE /
Edesa Biotech Receives C$14 million for COVID-19 Study TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to
Read more →EDSAEdesa Biotech Reports Fiscal Year 2020 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal Year 2020 Results ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its busi
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2020 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2020 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2020 and provided an update on
Read more →EDSAEdesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders TORONTO, ON / ACCESSWIRE /
Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreem
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2020 Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Fiscal 1st Quarter 2020 Results ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 and provided an update on
Read more →EDSAEdesa Biotech Announces $4.36 Million Registered Direct Offering TORONTO, ON / ACCESSWIRE /
Edesa Biotech Announces $4.36 Million Registered Direct ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements with certain institut
Read more →EDSAEdesa Biotech Reports Financial Results for Short Period Fiscal Year TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Financial Results for Short Period Fiscal ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September 30, 2019 and provid
Read more →EDSA(Date of earliest event reported): August 30,
SECTION 13 OR 15(d) OF EXCHANGE ACT OF 1934 (Date of earliest event reported): August 30, Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No
Read more →EDSAEdesa Biotech Reports Quarterly Financial Results TORONTO, ON / ACCESSWIRE /
Edesa Biotech Reports Quarterly Financial Results ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on it
Read more →EDSAEdesa Biotech and Stellar Biotechnologies Complete Business Combination TORONTO
Edesa Biotech and Stellar Biotechnologies Complete Business Combination TORONTO, June 7, 2019 /PRNewswire/ - Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (
Read more →EDSAStellar Biotechnologies Reports Second Quarter Financial Results
Stellar Biotechnologies Reports Second Quarter Financial Results LOS ANGELES, May 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today rep
Read more →EDSAStellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement LOS ANGELES, March 8, 2019 /PRNewswire/ - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has exe
Read more →EDSAStellar Biotechnologies Reports First Quarter Financial Results
Stellar Biotechnologies Reports First Quarter Financial Results LOS ANGELES, Feb. 5, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today rep
Read more →EDSAStellar Biotechnologies Reports Fiscal Year 2018 Financial Results
Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results LOS ANGELES, Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today
Read more →EDSAStellar Biotechnologies Reports Third Quarter Financial Results
Stellar Biotechnologies Reports Third Quarter Financial Results LOS ANGELES, Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus a
Read more →EDSAStellar Biotechnologies Announces Pricing of $5.5 Million Public Offering
Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering LOS ANGELES, May 11, 2018 /PRNewswire/ - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheime
Read more →EDSAStellar Biotechnologies Announces One-for-Seven Reverse Split
Stellar Biotechnologies Announces One-for-Seven Reverse Split LOS ANGELES, April 27, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy development pipelines, today is announcing a one-for-seven re
Read more →EDSAStellar Biotechnologies Reports First Quarter 2018 Financial Results
Stellar Biotechnologies Reports First Quarter 2018 Financial Results LOS ANGELES, Feb. 7, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, di
Read more →EDSAStellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors
Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors LOS ANGELES, Jan. 25, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzh
Read more →EDSAStellar Biotechnologies Reports Fiscal Year 2017 Financial Results - Company prepares to support expanded market opportunities - Expenditures in line with management plans
Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results - Company prepares to support expanded market opportunities - Expenditures in line with management plans LOS ANGELES, Dec. 1, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufac
Read more →EDSAStellar Biotechnologies Reports Third Quarter 2017 Financial Results - Company prepares for collaborators' Phase 2 clinical results
Stellar Biotechnologies Reports Third Quarter 2017 Financial Results LOS ANGELES, Calif., August 9, 2017 - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines, today reported financial
Read more →EDSAStellar Biotechnologies Reports Second Quarter 2017 Financial Results - Late-stage customer clinical studies drive plans for increased capacity. - Operating expenses in line with expectations.
Stellar Biotechnologies Reports Second Quarter 2017 Financial Results customer clinical studies drive plans for increased capacity. expenses in line with expectations. LOS ANGELES, Calif., May 9, 2017 - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of
Read more →EDSAStellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology - Stellar to receive upfront fee and future royalties - Matrivax to acquire proprietary rights to C. difficile technology and patent LOS
Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology LOS ANGELES, Calif. and BOSTON, Mass. - March 13, 2017 - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy development pipelines, a
Read more →EDSAStellar Biotechnologies Reports First Quarter 2017 Financial Results - Company continues scale-up initiatives to support greater production capacity.
Stellar Biotechnologies Reports First Quarter 2017 Financial Results - Company continues scale-up initiatives to support greater production capacity. LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein
Read more →EDSAStellar Biotechnologies Reports Fiscal Year 2016 Financial Results Broader customer base drives higher product sales volumes and revenue.
Stellar Biotechnologies Reports Fiscal Year 2016 Financial Results LOS ANGELES, Calif., December 14, 2016 - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzhei
Read more →EDSAStellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors
Stellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors LOS ANGELES, Calif., December 9, 2016 - Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targ
Read more →EDSAStellar Biotechnologies Announces Pricing of $6.75 Million Registered Direct Offering PORT HUENEME, CA -- 6/30/16 -- Stellar Biotechnologies, Inc. ( Stellar or the Company ) (NASDAQ: SBOT), the leader in sustainable manu
Stellar Biotechnologies Announces Pricing of $6.75 Million Registered Direct Offering PORT HUENEME, CA -- 6/30/16 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announce
Read more →EDSAand Neovacs Sign Joint Venture Agreement to
Stellar Biotechnologies and Neovacs Sign Joint Venture Agreement to Manufacture Conjugated Therapeutic Vaccines with Stellar KLH PORT HUENEME, CA, PARIS and BOSTON, (May 11, 2016) - Stellar Biotechnologies, Inc. ("Stellar") (Nasdaq: SBOT) and Neovacs S.A. ("Neovacs") (Alterne
Read more →EDSAStellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights PORT HUENEME, CA, (
Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights PORT HUENEME, CA, (May 09, 2015) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (Nasdaq: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KL
Read more →EDSAStellar Biotechnologies Announces Results of Special Meeting of Shareholders PORT HUENEME, CA--(Marketwired
Stellar Biotechnologies Announces Results of Special Meeting of Shareholders PORT HUENEME, CA--(Marketwired - Oct 29, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hem
Read more →EDSAStellar Biotechnologies Issues Corporate Update PORT HUENEME, CA -- 10/23/15 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyho
Stellar Biotechnologies Issues Corporate Update PORT HUENEME, CA -- 10/23/15 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today issued a corporate upda
Read more →EDSAStellar Biotechnologies Provides Update on Anticipated Listing on the NASDAQ Capital Market and Announces Meeting and Record Date for the Special Meeting of Shareholders on
Stellar Biotechnologies Provides Update on Anticipated Listing on the NASDAQ Capital Market and Announces Meeting and Record Date for the Special Meeting of Shareholders on October 29, 2015 PORT HUENEME, CA--(Marketwired - Sep 15, 2015) - Stellar Biotechnologies, Inc. ("Stellar"
Read more →EDSAStellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market PORT HUENEME, CA, (
Stellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market PORT HUENEME, CA, (August 28, 2015) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the leader in sustainable manufactu
Read more →EDSAStellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights PORT HUENEME, CA, (
Stellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights PORT HUENEME, CA, (August 10, 2015) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the leader in sustainable manufacture of Keyhole Limpet
Read more →EDSAStellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations Stellar Secures Strategic Site in Mexico for Exclusive Sustainable KLH Production Port Hueneme, CA (
Stellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations Stellar Secures Strategic Site in Mexico for Exclusive Sustainable KLH Production Port Hueneme, CA (July 28, 2015) Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SB
Read more →EDSAStock Options Granted PORT HUENEME, CA, (
Stock Options Granted PORT HUENEME, CA, (June 12, 2015) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH) announces the grant of incentive stock options to certain non-employee directors to purchase an aggregate of 50,000 common shares o
Read more →EDSACorporate Presentation OTCQB: SBOTF / TSX-V: KLH www.StellarBiotech.com www.KLHsite.org Safe Harbor This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
Corporate Presentation OTCQB: SBOTF / TSX-V: KLH www.StellarBiotech.com This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For
Read more →EDSAStellar Biotechnologies Reports Year-End 2014 Financial Results Company to Hold Conference Call at 1:30 p.m. ET Today PORT HUENEME, CA--(Marketwired
Stellar Biotechnologies Reports Year-End 2014 Financial Results Company to Hold Conference Call at 1:30 p.m. ET Today PORT HUENEME, CA--(Marketwired - Nov 13, 2014) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sus
Read more →EDSAStellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies PORT HUENEME, CA, (
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies PORT HUENEME, CA, (November 11, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH) and Araclon B
Read more →EDSAStellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma PORT HUENEME, CA, (
Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma PORT HUENEME, CA, (October 23, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH) and Biovest
Read more →EDSANOTICE OF CHANGE OF FINANCIAL YEAR-END
NOTICE OF CHANGE OF FINANCIAL YEAR-END British Columbia Securities Commission Alberta Securities Commission Re: Stellar Biotechnologies, Inc. (the "Company") Notice Pursuant to Section 4.8 of National Instrument 51-102 Pursuant to Section 4.8 of National Instrument 51-102 Co
Read more →EDSASTELLAR BIOTECHNOLOGIES, INC. AUDIT COMMITTEE CHARTER 1. Charter. This charter (this " Charter ") governs the operations of the Audit Committee (the " Committee ") of the Board of Directors (the " Board ") of Stellar Bio
STELLAR BIOTECHNOLOGIES, INC. AUDIT COMMITTEE CHARTER This charter (this "Charter") governs the operations of the Audit Committee (the "Committee") of the Board of Directors (the "Board") of Stellar Biotechnologies, Inc. (the "Company"). The Committee shall review and reassess
Read more →EDSAStellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments PORT HUENEME, CA, (
Stellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments PORT HUENEME, CA, (July 10, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), a leader in sustainable manufacture of Keyhole Limp
Read more →EDSACondensed Interim Consolidated Financial
Condensed Interim Consolidated Financial For the Nine Months Ended May 31, 2014 (Unaudited - Prepared by Management) NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not
Read more →EDSAStellar Biotechnologies, Inc. Corporate Presentation June 2014 www.StellarBiotech.com www.KLHsite.org (OTCQB: SBOTF) (TSX V: KLH) This presentation may contain forward-looking statements within the meaning of Section 27A
www.StellarBiotech.com This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the
Read more →EDSAStellar Biotechnologies Appoints Two Members to Scientific Advisory Board PORT HUENEME, CA, (
Stellar Biotechnologies Appoints Two Members to Scientific Advisory Board PORT HUENEME, CA, (June 6, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH) announced today the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson,
Read more →EDSASTELLAR BIOTECHNOLOGIES, INC. 332 E. Scott Street Port Hueneme, California 93041 (the "Company") NOTICE OF CHANGE OF AUDITOR TO: D&H GROUP LLP, CHARTERED ACCOUNTANTS AND TO: MOSS ADAMS LLP, CERTIFIED PUBLIC ACCOUNTANTS N
STELLAR BIOTECHNOLOGIES, INC. Port Hueneme, California 93041 NOTICE OF CHANGE OF AUDITOR TO: D&H GROUP LLP, CHARTERED ACCOUNTANTS AND TO: MOSS ADAMS LLP, CERTIFIED PUBLIC ACCOUNTANTS NOTICE IS HEREBY GIVEN that, on the advice of the Audit Committee of the Company, the Board
Read more →EDSAStellar Biotechnologies Releases Corporate Video PORT HUENEME, CA, (
Stellar Biotechnologies Releases Corporate Video PORT HUENEME, CA, (May 20, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the launch of its corporate video highlighting the Company's business of manufacturin
Read more →EDSAStellar Biotechnologies to Present at Two Upcoming Conferences PORT HUENEME, CA, (
Stellar Biotechnologies to Present at Two Upcoming Conferences PORT HUENEME, CA, (May 15, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announces that Company Executives are scheduled to present at two upcoming conferences. Fra
Read more →EDSAStellar Biotechnologies Retains Stonegate for Institutional Outreach PORT HUENEME, CA, (
Stellar Biotechnologies Retains Stonegate for Institutional Outreach PORT HUENEME, CA, (May 7, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH) announced today it has retained Stonegate, Inc. ("Stonegate") to provide institutional i
Read more →EDSAStellar Biotechnologies Launches New Corporate Website The New Website Showcases Stellar's Core KLH Products, Breakthroughs in Aquaculture Science, and Strategic Expansion of its Immunotherapy Program in a User-friendly
Stellar Biotechnologies Launches New Corporate Website The New Website Showcases Stellar's Core KLH Products, Breakthroughs in Aquaculture Science, and Strategic Expansion of its Immunotherapy Program in a User-friendly Platform PORT HUENEME, CA, (May 2, 2014) -- Stellar Biotec
Read more →EDSAStellar Biotechnologies to Host Corporate Update and Second Quarter 2014 Results Conference Call on April 10 PORT HUENEME, CA, (
Stellar Biotechnologies to Host Corporate Update and Second Quarter 2014 Results Conference Call on April 10 PORT HUENEME, CA, (April 04, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture
Read more →EDSAStellar Biotechnologies Presenting Today at 2014 TSX Venture 50 Spotlight Event PORT HUENEME, CA, (
Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50 Spotlight Event PORT HUENEME, CA, (April 1, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced that the company is presenting today at the 2014 TSX Venture 50
Read more →EDSAStellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference Port Hueneme, CA (
Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference Port Hueneme, CA (March 3, 2014) Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX-V: KLH) today announced the presentation of a poster at the Gordon Research C
Read more →EDSASTELLAR BIOTECHNOLOGIES TO PRESENT AT the 26 th Annual ROTH CAPITAL GROWTH CONFERENCE PORT HUENEME, CA, (
STELLAR BIOTECHNOLOGIES TO PRESENT AT the 26th Annual ROTH CAPITAL GROWTH CONFERENCE PORT HUENEME, CA, (February 27, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),) a company focused in the immunotherapy arena with world-leading
Read more →EDSAStellar Biotechnologies Reports on Annual General and Special Meeting PORT HUENEME, CA, (
Stellar Biotechnologies Reports on Annual General and Special Meeting PORT HUENEME, CA, (February 18, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announces that the Company held its Annual General and Special Meeting of Shareh
Read more →EDSAStellar Biotechnologies Named 2014 TSX Venture 50 Company PORT HUENEME, CA, (
Stellar Biotechnologies Named 2014 TSX Venture 50 Company PORT HUENEME, CA, (February 13, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today that the Company has been named to the 2014 TSX Venture 50 , an exclusive ra
Read more →EDSAStellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference PORT HUENEME, CA, (
Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference PORT HUENEME, CA, (February 12, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today the presentation of a poster at Aquaculture
Read more →EDSASTELLAR BIOTECHNOLOGIES, INC. TO PRESENT AT TWO INVESTOR CONFERENCES IN JANUARY PORT HUENEME, CA, (
STELLAR BIOTECHNOLOGIES, INC. TO PRESENT AT TWO INVESTOR CONFERENCES IN JANUARY PORT HUENEME, CA, (January 6, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today that the Company will present at two upcoming investor c
Read more →EDSAStellar Biotechnologies Issues Year-End Results and Highlights from 2013 PORT HUENEME, CA, (
Stellar Biotechnologies Issues Year-End Results and Highlights from 2013 PORT HUENEME, CA, (January 2, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today the filing of its annual report for the fiscal year ended Augus
Read more →EDSASTELLAR BIOTECHNOLOGIES, INC. ANNOUNCES MEETING AND RECORD DATE AND APPROVAL OF ADVANCE NOTICE POLICY PORT HUENEME, CA, (
STELLAR BIOTECHNOLOGIES, INC. ANNOUNCES MEETING AND RECORD DATE AND APPROVAL OF ADVANCE NOTICE POLICY PORT HUENEME, CA, (December 27, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),) announced today that it will hold an annual ge
Read more →Competitive Position
How EDSA ranks across every disease it competes inCompetitive Position is a premium feature
See how EDSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial